'We are delighted with this significant step forward for Drovelis®, as it means more choice for women in need of highly effective and convenient medical therapy for family planning', - said Erik Bogsch, Chairman of Gedeon Richter Plc. 'We remain committed to the development of female healthcare products, which improve quality of life for the female population in all age groups.'

About Drovelis®

Drovelis® is Richter's brand name for a novel oral contraceptive product composed of 15 mg estetrol (E4), its unique native estrogen acting selectively in tissues and 3 mg drospirenone. The E4 Freedom studies were open-label single arm trials and they were aimed to assess the safety and efficacy of the product in over 1,550 participants in Europe/Russia and approximately 2,150 participants in the US/Canada, over a period of 13 cycles.

For further information:

Investors: Katalin Ördög: +36 1 431 5680

Media: Zsuzsa Beke: +36 1 431 4888

Attachments

  • Original document
  • Permalink

Disclaimer

Gedeon Richter plc published this content on 20 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2021 15:06:02 UTC.